Sucampo ending cobiprostone development

Sucampo Pharmaceuticals Inc. (NASDAQ:SCMP) said it will discontinue development of cobiprostone ( SPI-8811) following a futility analysis of a Phase IIa study to prevent oral mucositis in head and neck cancer patients. Sucampo said the candidate's clinical benefit was not sufficient to support the study's continuation.

In April, Sucampo discontinued development of the prostone chloride channel 2 ( CLCN2; CIC-2) agonist to treat proton pump inhibitor (PPI)-refractory non-erosive reflux disease (NERD) and symptomatic gastroesophageal reflux disease (sGERD) (see BioCentury Extra, April 19). ...